Evidence-based public policy making formedicines across countries: findings andimplications for the future

Simple item page
dc.contributor.authorGodman, Brian
dc.contributor.authorFadare, Joseph
dc.contributor.authorKwon, Hye-Young
dc.contributor.authorZampirolli Dias, Carolina
dc.contributor.authorKurdi, Amanj
dc.contributor.authorDias God ́oi, Isabella Piassi
dc.contributor.authorKibuule, Dan
dc.contributor.authorHoxha, Iris
dc.contributor.authorOpanga, Sylvia
dc.contributor.authorSaleem, Zikria
dc.contributor.authorBochenek, Tomasz
dc.contributor.authorMarkovi ́c-Pekovi ́c, Vanda
dc.contributor.authorMardare, Ileana
dc.contributor.authorKalungia, Aubrey C
dc.contributor.authorCampbel, Stephen
dc.contributor.authorAllocati, Eleonora
dc.contributor.authorPisana, Alice
dc.contributor.authorMartin, Antony P
dc.contributor.authorMeyer, Johanna C
dc.date.accessioned2023-08-21T09:45:32Z
dc.date.available2023-08-21T09:45:32Z
dc.date.issued2021
dc.descriptionJournal article
dc.description.abstractim:Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence ofnon-communicable diseases (NCDs) and new premium priced medicines for cancer, orphan diseases andother complex areas. This is difficult to sustain without reforms.Methods:Extensive narrative review ofpublished papers and contextualizing the findings to provide future guidance.Results:New models arebeing introduced to improve the managed entry of new medicines including managed entry agreements,fair pricing approaches and monitoring prescribing against agreed guidance. Multiple measures have alsosuccessfully been introduced to improve the prescribing of established medicines. This includes encour-aging greater prescribing of generics and biosimilars versus originators and patented medicines in a classto conserve resources without compromising care. In addition, reducing inappropriate antibiotic utiliza-tion. Typically, multiple measures are the most effective.Conclusion:Multiple measures will be needed toattain and retain universal healthcare. Keywords:antimicrobials•biosimilars•COVID-19•demand-side measures•generics•guidelines•managedentry•oncology•orphan medicines•quality indicators•statins
dc.description.sponsorshipUniversity of Strathclyde, Mokwon University, Busitema University
dc.identifier.citationGodman, B., Fadare, J., Kwon, H. Y., Dias, C. Z., Kurdi, A., Dias Godoi, I. P., ... & Meyer, J. C. (2021). Evidence-based public policy making for medicines across countries: findings and implications for the future. Journal of comparative effectiveness research, 10(12), 1019-1052.
dc.identifier.issn2042-6305
dc.identifier.other2042-6313
dc.identifier.urihttps://doi.org/10.60682/fpxk-n629
dc.language.isoen
dc.publisherFuture Medicine Ltd
dc.subjectResearch Subject Categories::MEDICINE::Physiology and pharmacology::Pharmacological research::Clinical pharmacology
dc.titleEvidence-based public policy making formedicines across countries: findings andimplications for the future
dc.typeArticle
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
Department of Clinical Phamacology